Rebiotix is on the forefront of an exciting potential medical breakthrough

Harnessing the Power of the Human Microbiome

Video play time is 1:00 minute.

Rebiotix Inc is a clinical stage biotechnology company founded to revolutionize the treatment of debilitating gastrointestinal (GI) diseases by harnessing the power of the human microbiome.

The company is on the forefront of an exciting potential medical breakthrough with our MRT™ drug platform.  The MRT drug platform is for delivering healthy, live, human-derived microbes into a sick patient’s intestinal tract to treat disease.

Rebiotix looks to deliver on the promise of restoring the gut microbiota via a standardized and stabilized drug that has been developed and tested under the auspices of a regulatory authority.

Key Milestones in Harnessing the Power of the Human Microbiome

2011

  • Rebiotix was founded with $5M

2012

  • Pre-Investigational New Drug (IND) meeting with FDA for RBX2660

2013

  • FDA IND granted
  • Fast Track designation granted
  • PUNCH CD phase 2 trial enrolled for RBX2660 to treat recurrent Clostridium difficile

2014

  • $25M Series B round fundraising completed
  • FDA Orphan Drug designation granted
  • Results of PUNCH CD announced
  • PUNCH CD 2 (phase 2b) trial initiated
  • Development of oral formulation, RBX7455, started

2015

 2016

2017